The Switzerland-based miniMarrow, a spin-off project from the University of Lausanne, is developing a novel combination therapy to replace weekly and burdensome transfusions, which will significantly improve the quality of life of leukemic patients. The company's approach involves the in-situ production of blood components, which will be a disruptive technology in the field of transfusion medicine. By sustainably delivering cells, miniMarrow aims to transform the future of transfusion medicine and provide a more efficient and effective treatment option for patients with leukemia.